Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pugh

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203Ann H Klopp, Anamaria R Yeung, Snehal Deshmukh, et al.
Neuro-Oncology|June 3, 2022
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539C Leland Rogers, Stephanie L Pugh, Michael A Vogelbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III TrialAnamaria R Yeung, Snehal Deshmukh, Ann H Klopp, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2021
Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126William A Hall, Snehal Deshmukh, Deborah W Bruner, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2021
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical TrialChristopher U Jones, Stephanie L Pugh, Howard M Sandler, et al.
JAMA Oncology|April 20, 2023
Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical TrialSamuel Ryu, Snehal Deshmukh, Robert D Timmerman, et al.
Cancer|December 29, 2022
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126Andrew M McDonald, Lyudmila DeMora, Eddy S Yang, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203Ann H Klopp, Anamaria R Yeung, Snehal Deshmukh, et al.
Neuro-Oncology|June 3, 2022
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539C Leland Rogers, Stephanie L Pugh, Michael A Vogelbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III TrialAnamaria R Yeung, Snehal Deshmukh, Ann H Klopp, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2021
Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126William A Hall, Snehal Deshmukh, Deborah W Bruner, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2021
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical TrialChristopher U Jones, Stephanie L Pugh, Howard M Sandler, et al.
JAMA Oncology|April 20, 2023
Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical TrialSamuel Ryu, Snehal Deshmukh, Robert D Timmerman, et al.
Cancer|December 29, 2022
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126Andrew M McDonald, Lyudmila DeMora, Eddy S Yang, et al.
Pageof 23